Sign up to save your podcasts
Or
Share A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy
In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell transplantation with post-transplant cyclophosphamide.
Featured Articles:
- Wiskott-Aldrich Syndrome: A retrospective study on 577 patients defines the genotype as a predictive biomarker for disease severity and survival
- Loss of Dnmt3a increased self-renewal and resistance to pegylated interferon-alpha in JAK2-V617F-positive myeloproliferative neoplasms
- Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell transplantation with post-transplant cyclophosphamide.
Featured Articles:
- Wiskott-Aldrich Syndrome: A retrospective study on 577 patients defines the genotype as a predictive biomarker for disease severity and survival
- Loss of Dnmt3a increased self-renewal and resistance to pegylated interferon-alpha in JAK2-V617F-positive myeloproliferative neoplasms
- Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
More shows like Blood Podcast
View all
TED Talks Daily
11,140 Listeners
JAMA Editors' Summary
141 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
500 Listeners
Hematologic Oncology Update
75 Listeners
The Hematologist
26 Listeners
Core IM | Internal Medicine Podcast
1,156 Listeners
VJHemOnc Podcast
2 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
The Curious Clinicians
373 Listeners
EHA Unplugged
1 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
190 Listeners
WolverHeme Happy Hour
30 Listeners
HemeTalks: Conversations in Hematology Education
4 Listeners